Boston Pharmaceuticals, a clinical stage biopharmaceutical firm, has signed a licensing and equity agreement with Switzerland-based Novartis.
It was reported yesterday that the contract has been signed for the global rights to three of Novartis's anti-infective candidates for the potential treatment of Gram-negative infections.
Under the terms of the deal, the company purchased global rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. The anti-infective drug candidates are part of the Novartis infectious diseases portfolio, which have potential to address the requirement of new agents for the treatment of antibiotic resistant Gram-negative infections.
The candidates covered by the deal are LYS228 monobactam, IID572 beta-lactamase inhibitor and MAK181 oral LpxC inhibitor for Pseudomonas infections. The LYS228 monobactam has entered inti phase 2 clinical development. It showed activity against CRE with resistance caused by serine beta-lactamases (SBLs) and/or metallo beta-lactamases (MBLs). The IID572 is a beta-lactamase inhibitor, which can be used in combination with LYS228 or other beta-lactam antibiotics to expand their use against difficult-to-treat infections caused by a broader spectrum of CRE.
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Ondine's Steriwave proven effective against deadly Mucor fungus
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
bioMérieux launches rapid PCR test for equine respiratory diseases
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
Seegene presrnts CURECA conceptual video at ESCMID Global 2025
GC Biopharma's BARYTHRAX receives Korean regulatory approval
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management